Press Releases

Press Releases

  • Sep 30, 2019
    NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new U.S. Patent Covering Attention Deficit Hyperactivity Disorder strengthening the scope of NLS’ Patent Portfolio.

    READ PRESS RELEASE

  • Aug 13, 2019
    NLS Pharmaceutics Ltd. (NLS) Announces a Reexamination Certificate by the USPTO Further Strengthening their ADHD Use Patent Validity

    READ PRESS RELEASE

  • Jul 3, 2019
    NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio

    READ PRESS RELEASE

  • Mar 19, 2019
    NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS- 1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®

    READ PRESS RELEASE

  • Feb 21, 2019
    NLS-1 Pharma and Eurofarma Enter to an Exclusive Licensing Agreement to Develop and Commercialize Nolazol® for the Treatment of ADHD in Latin America

    READ PRESS RELEASE

  • Sept 1, 2018
    CEO of NLS-1 Pharma AG is honored with Several Illustrious Awards This Summer

    READ PRESS RELEASE

  • Mar 24, 2018
    NLS-1 Pharma Is Awarded “Best Quality of Life Improvement Pharmaceuticals Company – Central Europe” by Global Health & Pharma Magazine

    READ PRESS RELEASE

  • Feb 5, 2018
    NLS-1 Presents Positive Phase 2 Study Results for Mazindol at APSARD

    READ PRESS RELEASE   VIEW POSTER

  • Oct 31, 2017
    NLS-1 Pharma Announces Poster Presentation On Efficacy and Safety Data of a Controlled Release (CR) Formulation of Mazindol in Adults with ADHD at AACAP’s & APSARD’s Annual Meeting in the US

    READ PRESS RELEASE

  • Oct 9, 2017
    NLS-1 wins prestigious Innovation Award in Paris. Over 300 candidates participated in the race.

    READ MORE

  • May 31, 2017
    NLS-1 Pharma unveils positive phase 2 data for NLS-1 (Mazindol CR) in adults with ADHD, demonstrating significant improvement in symptoms

    READ PRESS RELEASE

  • May 26, 2017
    NLS-1 Pharma announces new information in support of the mechanism of action of its lead compound NLS-1 Mazindol CR

    READ PRESS RELEASE

  • May 16, 2017
    NLS-1 Pharma announces phase 2 study of NLS-1 (MAZINDOL) in adult ADHD patients has met all primary and secondary endpoints

    READ PRESS RELEASE

  • April 20, 2017
    NLS-1 Pharma Announces Presentations at 6th World Congress on ADHD

    READ PRESS RELEASE

  • April 18, 2017
    NLS-1 Pharma Announces Completion of Phase 2 Study for NLS-1, Its Lead ADHD Compound; New Investors, New Patents

    READ PRESS RELEASE

  • December 3, 2016
    NLS-1 Pharma Named Winner Of A Prestigous 2016 Healthcare & Life Sciences Award

    READ PRESS RELEASE

  • August 29, 2016
    NLS-1 Pharma announces start of its phase 2 trial for Mazindol in adult ADHD patients

    READ PRESS RELEASE

  • July 11, 2016
    Mazindol granted orphan drug designation in the US & Europe for treatment of Narcolepsy

    READ PRESS RELEASE

  • June 16, 2016
    FDA accepts IND for Phase II Study of Mazindol in Adults with ADHD

    READ PRESS RELEASE

  • May 12, 2016
    NLS-1 Pharma Announces IND submission for Controlled-Release Mazindol to Treat Adults with ADHD.

    READ PRESS RELEASE